https://www.prnewswire.com/news-releases/bayers-investigational-drug-riociguat-granted-fda-orphan-drug-designation-for-treatment-of-pulmonary-arterial-hypertension-and-chronic-thromboembolic-pulmonary-hypertension-225174802.html
/PRNewswire/ -- Bayer HealthCare today announced that the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development has granted two...
investigational drugorphan designationbayerriociguatgranted